Advertisement
Not a member of Pastebin yet?
Sign Up,
it unlocks many cool features!
- Pharma Sarms Powder MK-1775 Inhibits Wee1 Kinase CAS: 955365-80-7
- Just try a small order to start our cooperation, we will NOT make you down !
- Any products interested pls let me know I will give info.in details.
- kathelin@yccreate.com
- Skype:live:kathelin_4
- Product Name: MK-1775
- Product Name: 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one
- Synonyms: 2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one;MK-1775;MK-1775,MK1775;2-allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1,2-dihydropyrazolo[3,4-d]pyrimidin-3-one;2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one MK 1775;MK 1775 2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-6-(4-(4-methylpiperazin-1-yl)phenylamino)-1H-pyrazolo[3,4-d]pyrimidin-3(2H)-one;MK-1775, >=98%;MK-1175
- CAS: 955365-80-7
- MF: C27H32N8O2
- MW: 500.59538
- Detailed Descriptions of Mk-1775
- Synonyms AZD 1775
- MK-1775 is an inhibitor of the checkpoint kinase Wee1 (IC50 = 5.2 nM).1 It has been shown to inhibit the phosphorylation of Cdc2 at
- tryosine-15, which abrogates the G2 DNA damage checkpoint.1 In p53-deficient tumors that rely solely on the G2 checkpoint upon DNA
- damage, MK-1775, in combination with DNA-damaging chemotherapeutic agents, is reported to induce apoptosis in vitro and potentiate
- MK-1775 inhibits Wee1 kinase in an ATP-competitive manner. Compared to Wee1, MK-1775 displays 2- to 3-fold less potency against Yes with IC50 of 14 nM, 10-fold less potency against seven other kinases with >80% inhibition at 1 μM, and >100-fold selectivity over human Myt 1, another kinase that inhibits cyclin-dependent kinase 1 (CDC2) by phosphorylation at an alternative site (Thr14). By abrogating the DNA damage checkpoint via blockade of Wee1 activity in WiDr cells bearing mutated p53, MK-1775 treatment inhibits the basal phosphorylation of CDC2 at Tyr15 (CDC2Y15) with EC50 of 49 nM, and suppresses gemcitabine-, carboplatin- or cisplatin-induced phosphorylation of CDC2 and cell cycle arrest in a dose-dependent manner, with EC50 of 82 nM and 81 nM, 180 nM and 163 nM, as well as 159 nM and 160 nM, respectively. MK-1775 treatment alone at 30-100 nM has no significant antiproliferative effect in WiDr and H1299 cells, whereas MK-1775 at 300 nM, sufficient to inhibit Wee1 by >80%, displays moderate but significant antiproliferative effects by 34.1% in WiDr cells and 28.4% in H1299 cells.
- in vivo: MK-1775 treatment alone at ~20 mg/kg displays minimal antitumor effects against WiDr xenografts in rats with T/C of 69% at day 3. Antitumor efficacy by MK-1775 alone in the nude rat HeLa-luc and TOV21G-shp53 xenograft models models is also moderate.
- SARMs List
- MK-2866 (Ostarine)
- RAD-140 (Testolone)
- MK-677 (Ibutamoren; Nutrobal)
- LGD-4033 (Ligandrol; Anabolicum)
- S4 (Andarine)
- SR9009 (Stenabolic)
- SR9011
- YK11
- GW501516(GSK-516)
- AICAR
- S-23
- LGD-3303
- GW-0742
- MK-1775
Advertisement
Add Comment
Please, Sign In to add comment
Advertisement